SEARCH

SEARCH BY CITATION

References

  • Asai M., Hattori C., Iwata N. et al. (2006) The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J. Neurochem. 96, 533540.
  • Asso V., Ghilardi E., Bertini S. et al. (2008) α-Naphthylaminopropan-2-ol derivatives as BACE-1 inhibitors. ChemMedChem 3, 15301534.
  • Baxter E. W., Conway K. A., Kennis L. et al. (2007) 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (β-Site APP Cleaving Enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead. J. Med. Chem. 50, 42614264.
  • Beswick P., Charrier N., Clarke B. et al. (2008) BACE-1 inhibitors part 3: identification of hydroxyethylamines (HEAs) with nanomolar potency in cells. Bioorg. Med. Chem. Lett. 18, 10221026.
  • Björklund C., Oscarson S., Benkestock K. et al. (2010) Design and synthesis of potent and selective BACE-1 inhibitors. J. Med. Chem. 53, 14581464.
  • Cai H., Wang Y., McCarthy D., Wen H., Borchelt D. R., Price D. L. and Wong P. C. (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233234.
  • Cavalli A., Bolognesi M. L., Capsoni S. et al. (2007) A small molecule targeting the multifactorial nature of Alzheimer’s disease. Angew. Chem. Int. Ed. 46, 36893692.
  • Chang W. P., Koelsch G., Wong S. et al. (2004) In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J. Neurochem. 89, 14091416.
  • Chang W., Huang X., Downs D., Cirrito J., Koelsch G., Holzman D. M., Ghosh A. K. and Tang J. (2011) β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 25, 775784.
  • Charrier N., Clarke B., Cutler L. et al. (2008) Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability. J. Med. Chem. 51, 33133317.
  • Clarke B., Demont E., Dingwall C. et al. (2008a) BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs). Bioorg. Med. Chem. Lett. 18, 10111016.
  • Clarke B., Demont E., Dingwall C. et al. (2008b) BACE-1 inhibitors part 2: identification of hydroxyl ethylamines (HEAs) with reduced peptidic character. Bioorg. Med. Chem. Lett. 18, 10171021.
  • Cole D. C., Manas E. S., Stock J. R. et al. (2006) Acylguanidines as small-molecule β-Secretase inhibitors. J. Med. Chem. 49, 61586161.
  • Cole D. C., Stock J. R., Chopra R. et al. (2008) Acylguanidine inhibitors of β-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg. Med. Chem. Lett. 18, 10631066.
  • Cumming J. N., Le T. X., Babu S. et al. (2008) Rational design of novel, potent piperazinone and imidazolidinone BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 18, 32363241.
  • Cumming J., Babu S., Huang Y. et al. (2010) Piperazine sulfonamide BACE-1 inhibitors: design, synthesis, and in vivo characterization. Bioorg. Med. Chem. Lett. 20, 28372842.
  • Durham T. B. and Shepherd T. A. (2006) Progress toward the discovery and development of efficacious BACE inhibitors. Curr. Opin. Drug Discov. Dev. 9, 776791.
  • Freskos J. N., Fobian Y. M., Benson T. E. et al. (2007a) Design of potent inhibitors of human β-secretase. Part 1. Bioorg. Med. Chem. Lett. 17, 7377.
  • Freskos J. N., Fobian Y. M., Benson T. E. et al. (2007b) Design of potent inhibitors of human β-secretase. Part 2. Bioorg. Med. Chem. Lett. 17, 7881.
  • Fukumoto H., Takahashi H., Tarui N. et al. (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer’s disease. J. Neurosci. 30, 1115711166.
  • Ghosh A. K. (2010) Aspartic acid proteases as therapeutic targets in Methods and Principles in Medicinal Chemistry (Mannhold R., Kubinyi H. and Folkers G., eds), Vol. 45, pp. 441479. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • Ghosh A. K., Shin D., Downs D., Koelsch G., Lin X., Ermolieff J. and Tang J. (2000) Design of potent inhibitors for human brain memapsin 2 (β-secretase). J. Am. Chem. Soc. 122, 35223523.
  • Ghosh A. K., Bilcer G., Harwood C. et al. (2001) Structure-based design: potent inhibitors of human brain memapsin 2 (β-secretase). J. Med. Chem. 44, 28652868.
  • Ghosh A. K., Devasamudram T., Hong L., DeZutter C., Xu X., Weerasena V., Koelsch G., Bilcer G. and Tang J. (2005) Structure based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase). Bioorg. Med. Chem. Lett. 15, 1520.
  • Ghosh A. K., Kumaragurubaran N., Hong L. et al. (2007) Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J. Med. Chem. 50, 23992407.
  • Ghosh A. K., Gemma S. and Tang J. (2008a) Beta-secretase as a therapeutic target for Alzheimer’s disease. Neurotherapeutics 3, 399408.
  • Ghosh A. K., Kumaragurubaran N., Hong L. et al. (2008b) Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X ray structure, and in vivo evaluation. Bioorg. Med. Chem. Lett. 18, 10311036.
  • Hamada Y., Igawa N., Ikari H. et al. (2006) β-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorg. Med. Chem. Lett. 16, 43544359.
  • Hanessian S., i Shao Z., Betschart C., Rondeau J.-M., Neumann U. and Tintelnot-Blomle M. (2010) Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors. Bioorg. Med. Chem. Lett. 20, 19241927.
  • Hey J. A., Koelsch G., Bilcer G., Jacobs A., Tolar M., Tang J., Ghosh A. K. and Hsu H. H. (2008) Single Dose Administration of the β-Secretase Inhibitor CTS21166 (ASP1720) Reduces Plasma Aβ40 in Human Subjects. International Conference on Alzheimer’s Disease (ICAD), Chicago, IL.
  • Hom R. K., Fang L. Y., Mamo S. et al. (2003) Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human β-Secretase. J. Med. Chem. 46, 17991802.
  • Hom R. K., Gailunas A. F., Mamo S. et al. (2004) Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human β-secretase. J. Med. Chem. 47, 158164.
  • Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A. K., Zhang X. C. and Tang J. (2000) Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290, 150153.
  • Hsu H. H. (2010) Clinical trials for disease-modifying drugs such as BACE inhibitors, in BACE: Lead Target for Orchestrated Therapy of Allheimer’s Disease (John V., ed.), pp. 197216. John Wiley & Sons, Hoboken, NJ, USA.
  • Huang W., Lv D., Yu H. et al. (2010) Dual-target-directed 1,3-diphenylurea derivatives: BACE-1 inhibitor and metal chelator against Alzheimer’s disease. Bioorg. Med. Chem. 18, 56105615.
  • Hussain I., Hawkins J., Harrison D. et al. (2007) Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid β production in vivo. J. Neurochem. 100, 802809.
  • Iserloh U., Wu Y., Cumming J. N. et al. (2008a) Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 18, 414417.
  • Iserloh U., Pan J., Stamford A. W. et al. (2008b) Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg. Med. Chem. Lett. 18, 418422.
  • Jennings L. D., Cole D. C., Stock J. R. et al. (2008) Acylguanidine inhibitors of β-secretase: optimization of the pyrrole ring substituents extending into the S1′ substrate binding pocket. Bioorg. Med. Chem. Lett. 18, 767771.
  • Kimura T., Shuto D., Hamada Y. et al. (2005) Design and synthesis of highly active Alzheimer’s β-secretase (BACE-1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg. Med. Chem. Lett. 15, 211215.
  • Kimura T., Hamada Y., Stochaj M. et al. (2006) Design and synthesis of potent β-secretase (BACE-1) inhibitors with P1′ carboxylic acid bioisosteres. Bioorg. Med. Chem. Lett. 16, 23802386.
  • Koelsch G. (2008) Beta-Secretase Inhibitor CTS-21166 Reduces Plasma Abeta40 in Human Subjects. Keystone Symposium on Alzheimer’s Disease. Keystone, Colorado; March 24–28.
  • Kortum S. W., Benson T. E., Bienkowski M. J. et al. (2007) Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE-1. Bioorg. Med. Chem. Lett. 17, 33783383.
  • Lerchner A., Machauer R., Betschart C. et al. (2010) Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application. Bioorg. Med. Chem. Lett. 20, 603607.
  • Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M. and Ashe K. H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352357.
  • Li X., Bo H., Zhang X. C., Hartsuck J. A. and Tang J. (2010) Predicting memapsin 2 (beta-secretae) hydrolytic activity. Protein Sci. 19, 21752185.
  • Lindsley S. R., Moore K. P., Rajapakse H. A. et al. (2007) Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 17, 40574061.
  • Luo Y., Bolon B., Kahn S. et al. (2001) Mice deficient in BACE1, the Alzheimer’s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Neurosci. 4, 231232.
  • Maillard M. C., Hom R. K., Benson T. E. et al. (2007) Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human β-Secretase. J. Med. Chem. 50, 776781.
  • Malamas M. S., Erdei J., Gunawan I. et al. (2009) Aminoimidazoles as potent and selective human β-secretase (BACE1) inhibitors. J. Med. Chem. 52, 63146323.
  • Malamas M. S., Erdei J., Gunawan I. et al. (2010) Design and synthesis of 5,5′-disubstituted aminohydantoins as potent and selective human β-secretase (BACE-1) inhibitors. J. Med. Chem. 53, 11461158.
  • Meredith J. A., Björklund C., Adolfsson H. et al. (2010) P2′-truncated BACE-1 inhibitors with a novel hydroxethylene-like core. Eur. J. Med. Chem. 45, 542554.
  • Moka N. Y., Chadwick J., Kellett K. A. B., Hooper N. M., Johnson A. P. and Fishwick C. W. G. (2009) Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorg. Med. Chem. Lett. 19, 67706774.
  • Nantermet P. G., Rajapakse H. A., Stanton M. G. et al. (2009) Evolution of tertiary carbinamine BACE-1 inhibitors: Aβ reduction in rhesus CSF upon oral dosing. ChemMedChem 4, 3740.
  • Nishitomi K., Sakaguchi G., Horikoshi Y. et al. (2006) BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J. Neurochem. 99, 15551563.
  • Ohno M., Sametsky E. A., Younkin L. et al. (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer’s disease. Neuron 41, 2733.
  • Rajapakse H. A., Nantermet P. G., Selnick H. G. et al. (2006) Discovery of Oxadiazoyl Tertiary Carbinamine Inhibitors of β-Secretase (BACE-1). J. Med. Chem. 49, 72707273.
  • Roberds S. L., Anderson J., Basi G. et al. (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum. Mol. Genet. 10, 13171324.
  • Sankaranarayanan S., Price E. A., Wu G. et al. (2008) In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J. Pharmacol. Exp. Ther. 324, 957969.
  • Sankaranarayanan S., Holahan M. A., Colussi D. et al. (2009) First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J. Pharmacol. Exp. Ther. 328, 131140.
  • Sasaki H., Miki K., Kinoshita K. et al. (2010) β-Secretase (BACE-1) inhibitory effect of bioflavonoids. Bioorg. Med. Chem. Lett. 20, 45584560.
  • Sealy J. M., Truong A. P., Tso L. et al. (2009) Design and synthesis of cell potent BACE-1 inhibitors: structure–activity relationship of P1′ substituents. Bioorg. Med. Chem. Lett. 19, 63866391.
  • Selkoe D. J. and Schenk D. (2008) Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545584.
  • Stachel S. J., Coburn C. A., Steele T. G. et al. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J. Med. Chem. 47, 64476450.
  • Stachel S. J., Coburn C. A., Sankaranarayanan S. et al. (2006) Macrocyclic inhibitors of beta-secretase: functional activity in an animal model. J. Med. Chem. 49, 61476150.
  • Stanton M. G., Stauffer S. R., Gregro A. R. et al. (2007) Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of betaamyloid. J. Med. Chem. 50, 34313433.
  • Stauffer S. R., Stanton M. G., Gregro A. R. et al. (2007) Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation. Bioorg. Med. Chem. Lett. 17, 17881792.
  • Tang J. and Ghosh A. K. (2010) Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned? Aging 3, 1416.
  • Truong A. P., Tóth G., Probst G. D. et al. (2010) Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg. Med. Chem. Lett. 20, 62316236.
  • Turner R. T., III, Koelsch G., Hong L., Castanheira P., Ermolieff J., Ghosh A. K. and Tang J. (2001) Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 40, 1000110006.
  • Turner III R. T., Hong L., Koelsch G., Ghosh A. K. and Tang J. (2005) Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). Biochemistry 44, 105112.
  • Wångsell F., Russo F., Sävmarker J., Rosenquist Å., Samuelsson B. and Larhed M. (2009) Design and synthsis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic. Bioorg. Med. Chem. Lett. 19, 47114714.
  • Wångsell F., Gustafsson K., Kvarnström I. et al. (2010) Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core. Eur. J. Med. Chem. 45, 870882.
  • Wångsell F., Nordeman P., Sävmarker J. et al. (2011) Investigation of α-phenylnorstatine and α-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors. Bioorg. Med. Chem. 19, 145155.
  • Westerman M. A., Cooper-Blacketer D., Mariash A. et al. (2002) The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer’s disease. J. Neurosci. 22, 18581867.
  • Wolfe M. S. (2008) Gamma-secretase inhibition and modulation for Alzheimer’s disease. Curr. Alzheimer Res. 5, 158164.
  • Xu W., Chen G., Zhu W. and Zuo Z. (2010a) Molecular docking and structure–activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors. Bioorg. Med. Chem. Lett. 20, 62036207.
  • Xu W., Chen G., Zhu W. and Zuo Z. (2010b) Identification of a sub-micromolar, non-peptide inhibitor of b-secretase with low neural cytotoxicity through in silico screening. Bioorg. Med. Chem. Lett. 20, 57635766.
  • Zhu Y., Xiao K., Ma L. et al. (2009) Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and β-secretase. Bioorg. Med. Chem. 17, 16001613.
  • Zhu H., Young M. B., Nantermet P. G. et al. (2010) Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. Bioorg. Med. Chem. Lett. 20, 17791782.